Inferra AI / Company / AMPH
Amphastar Pharmaceuticals, Inc.
AMPH · Health Care
Last earnings Aug 6, 2026
Key results
Reports Net revenuequarter
$174.4 million
Reports Net Revenues of $174.4 million for the
SEC original ↗Amphastar Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
GAAP net incomequarter
$31.0 million
GAAP net income of $31.0 million, or $0.64 per share, for the second quarter - Adjusted non-GAAP
SEC original ↗Amphastar Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Net incomequarter
$40.9 million
net income of $40.9 million, or $0.85 per share, for the second quarter - Company to hold a conference call today at 2:00 p.
SEC original ↗Amphastar Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Revenuequarter
21%
We are pleased to report strong second-quarter performance, driven primarily by the continued momentum of BAQSIMI , which has quickly become a key driver of our revenue in 2025, with a 21% total sales increase compared to the same period last year, said Dr.
SEC original ↗Amphastar Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
AI analysis
Q2 2025 · reported Aug 7, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Headline figures
| Metric | Q2 2025 | Prior qtr | Year ago |
|---|---|---|---|
| Reports Net revenue | $174.4 million | — | — |
| GAAP net income | $31.0 million | — | — |
| Net income | $40.9 million | — | — |
| Revenue | 21% | — | — |
Guidance · company-stated
No guidance located in the held release
Capital allocation
Share Buyback Program On August 5, 2025, the Company s Board of Directors authorized a $50 million increase to the Company s share buyback program, which is expected to continue for an indefinite period of time.
The timing and actual number of shares repurchased will depend on a variety of factors including price, corporate and regulatory requirements, and other conditions.
Company-stated claims
Forward-looking · quadruple · production_deliveries
“However, we are planning to increase capacity at our plant in Rancho Cucamonga, CA with the goal of allowing us to eventually quadruple the number of units produced at this facility.”
10-K · Feb 26, 2026Event summary
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
No guidance located in the held release
Capital allocation
Share Buyback Program On August 5, 2025, the Company s Board of Directors authorized a $50 million increase to the Company s share buyback program, which is expected to continue for an indefinite period of time.
SEC original ↗Amphastar Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
The timing and actual number of shares repurchased will depend on a variety of factors including price, corporate and regulatory requirements, and other conditions.
SEC original ↗Amphastar Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
As a result, the Company is disclosing certain non-GAAP results, including (i) Adjusted non-GAAP net income (loss) and (ii) Adjusted non-GAAP diluted EPS, which generally excludes amortization expense, share-based compensation, impairment charges, expenses related to our acquisition of BAQSIMI , certain debt issuance costs, legal settlements, and other one-time events in order to supplement investors and other readers understanding and assessment of the Company s financial performance because the Company s management uses these measures internally for forecasting, budgeting, and measuring its operating performance.
SEC original ↗Amphastar Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Financial Instruments The Company s accompanying condensed consolidated balance sheets include the following financial instruments: cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, short-term borrowings, and long-term obligations.
SEC original ↗Amphastar Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
The carrying value of the Company s long-term obligations, with the exception of the convertible debt (see Note 13), approximates their fair value, as the stated borrowing rates are comparable to rates currently offered to the Company for instruments with similar maturities.
SEC original ↗Amphastar Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
The Company at times enters into interest rate swap contracts to manage its exposure to interest rate changes and its overall cost of long-term debt.
SEC original ↗Amphastar Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Strategy & priorities
(NASDAQ: AMPH) ( Amphastar or the Company ), a biopharmaceutical company focused on developing, manufacturing, and marketing complex generic and proprietary injectable, inhalation, and intranasal products, today reported results for the three months ended June 30, 2025.
SEC original ↗Amphastar Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
This quarter also marked a major strategic milestone with the announcement of the largest domestic infrastructure investment in our company s history, a multi-year plan to quadruple manufacturing capacity at our headquarters in Rancho Cucamonga.
SEC original ↗Amphastar Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
In particular, there can be no guarantee that our sales strategies will be successful, or that we will continue to experience significant sales of BAQSIMI .
SEC original ↗Amphastar Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
, a Delaware corporation (together with its subsidiaries, hereinafter referred to as the Company ), is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, including products with high technical barriers to market entry.
SEC original ↗Amphastar Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
These standards also establish a hierarchy that prioritizes observable and unobservable inputs used in measuring fair value of an asset or liability, as described below: Level 1 Inputs to measure fair value are based on quoted prices (unadjusted) in active markets on identical assets or liabilities; Level 2 Inputs to measure fair value are based on the following: (a) quoted prices in active markets on similar assets or liabilities, (b) quoted prices for identical or similar instruments in inactive markets, or (c) observable -14- Table of Contents AMPHASTAR PHARMACEUTICALS, INC.
SEC original ↗Amphastar Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Risks & headwinds
You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar s control.
SEC original ↗Amphastar Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Legal Proceedings 41 Item 1A.
SEC original ↗Amphastar Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Exhibits 44 Signatures 45 Table of Contents SPECIAL NOTE ABOUT FORWARD-LOOKING STATEMENT S This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements that involve substantial risks and uncertainties.
SEC original ↗Amphastar Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Forward-looking statements relate to future events or future financial performance or condition and involve known and unknown risks, uncertainties and other factors that could cause actual results, levels of activity, performance or achievement to differ materially from those expressed or implied by the forward-looking statements.
SEC original ↗Amphastar Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
In light of the significant risks and uncertainties to which our forward-looking statements are subject, you should not place undue reliance on or regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified timeframe, or at all.
SEC original ↗Amphastar Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
We discuss many of these risks and uncertainties in greater detail in this Quarterly Report and in our Annual Report on Form 10-K for the year ended December 31, 2025, particularly in Item 1A.
SEC original ↗Amphastar Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
32 documents- Q2 2026
- 8-KAMPH
- 10-QAMPH
- 8-KAMPH
- 8-KAMPH
- Q1 2026
- 8-KAMPH
- 8-KAMPH
- 10-QAMPH
- Q4 2025
- 8-KAMPH
- 8-KAMPH
- 8-KAMPH
- 8-KAMPH
- 10-KAMPH
- 8-KAMPH
- EX-99AMPH
- Q3 2025
- 8-KAMPH
- 10-QAMPH
- 8-KAMPH
- Q2 2025
- 8-KAMPH
- 8-KAMPH
- 8-KAMPH
- 10-QAMPH
- 8-KAMPH
- Q1 2025
- 8-KAMPH
- 10-QAMPH
- 8-KAMPH
- Q4 2024
- 10-KAMPH
- 8-KAMPH
- Q3 2024
- 10-QAMPH
- 8-KAMPH
- Q2 2024
- 8-KAMPH
- 10-QAMPH
- Q4 2023
- 10-KAMPH
Earnings releases
8 documentsPresentations
0 documentsNo presentations for Amphastar Pharmaceuticals, Inc. are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Amphastar Pharmaceuticals, Inc. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.